TerrAscend Shareholders Approve Share Consolidation Ahead of U.S. Uplist

TerrAscend (TSND.TO ) shareholders on August 24, 2026 approved a share consolidation that clears the way for the multistate operator to shrink its share count by as much as twenty-fold, the mechanical prerequisite for a listing on the New York Stock Exchange or Nasdaq. The special resolution passed with 143,095,552 votes in favor, 99.25% of votes cast at the virtual special meeting, against 141,435 withheld, the company announced after the meeting.

The approval does not itself consolidate anything. It hands the board a one-year window, running to August 24, 2027, to execute a reverse split at any whole-number ratio between one-for-five and one-for-twenty, across all of the company’s common shares, unlisted exchangeable shares, and preferred shares. The board picks the ratio and the timing, and can walk away entirely; if it does nothing within the window, the authority lapses.

“Today’s shareholder vote is an important milestone for TerrAscend and marks the completion of a key step in our preparation to list on a major U.S. stock exchange,” Executive Chairman Jason Wild said in the company’s announcement. “We appreciate the support of our shareholders and their confidence in our strategy.”

Wild is not a disinterested party in the outcome. The company’s definitive proxy statement, filed July 6, 2026, shows he directly and indirectly controlled 83,780,261 common shares, 27.10% of eligible votes, as of the June 30, 2026 record date, and beneficially owned 29.65% of the class. The resolution needed two-thirds of votes cast to pass; it cleared that bar with room to spare even setting aside his position.

What the Consolidation Does

Both the NYSE and Nasdaq require a minimum bid price of $4.00 per share for a new listing, the proxy states. TerrAscend’s common shares closed at $0.68 on the Toronto Stock Exchange on the record date, so no ratio inside the approved range gets the stock to $4.00 on arithmetic alone. At one-for-five, the record-date price translates to roughly $3.40; at one-for-twenty, to roughly $13.60. The proxy says the board will choose primarily on the share price at the time and its expected stability, which points to the board needing the higher end of the range, or a materially higher market price, before pulling the trigger.

The math on the other side of the split is spelled out in the filing. As of the record date, TerrAscend had 309,175,647 common shares, 63,492,037 exchangeable shares, and 11,325 preferred shares outstanding. A one-for-five consolidation takes the common count to about 61.8 million; one-for-twenty takes it to about 15.5 million. Fractional shares created by the consolidation are cancelled for no consideration rather than cashed out.

Approval also does not mean a U.S. listing application follows. The proxy states that no final decision has been made on any exchange application, and that any listing remains subject to conditions including further board approval, TSX approval if required by TSX rules, acceptance by the U.S. exchange, satisfaction of listing standards, regulatory review, and market conditions.

The Road to the Vote

The special meeting was the visible endpoint of a preparation track the company has described in steps since June. TerrAscend called the meeting on June 5, 2026, saying the consolidation was intended to position it to meet share-price criteria at major U.S. exchanges and that it had been in consultation with those exchanges. Wild framed the listing question at the time as “no longer a question of if, it is a question of when,” and pointed to 2022, when the company became an SEC filer, as the start of the positioning.

The proxy followed on July 6, 2026, setting the one-for-five to one-for-twenty range and the board-discretion structure. On August 20, 2026, four days before the vote, the company renewed its $10 million share repurchase program, authorizing buybacks of up to 10,000,000 shares over 12 months starting August 24, 2026, with Wild citing progress toward a U.S. exchange listing as part of the rationale.

The backdrop the company points to is the federal rescheduling decision of April 23, 2026, which moved marijuana in FDA-approved drug products and marijuana under a state medical license to Schedule III, effective April 28, 2026. MyCannabis has tracked the resulting exchange-listing race across the sector, from Trulieve’s landmark NYSE listing and its closing bell ceremony to Curaleaf’s reverse split and Ascend Wellness’s reverse-split vote, alongside TerrAscend’s own buyback renewal coverage.

What the Approval Does and Does Not Do

The vote’s immediate legal effect is narrow: it amends the company’s articles, once the board files them, to permit the consolidation. Everything else is optionality. The board retains sole discretion over whether to implement, at what ratio, and when, and the filing is explicit that shareholder approval creates no obligation to proceed with either the split or a listing application.

There are also constraints stacked on top. The consolidation requires TSX acceptance and confirmation that TerrAscend would still meet the exchange’s continued listing requirements afterward. The company warns in the proxy that a consolidation may not produce or sustain a higher trading price. And the federal footing remains partial: the April rescheduling left adult-use marijuana outside FDA-approved products and state medical licenses in Schedule I, a distinction the company carries in its own risk language.

TerrAscend, headquartered in Mississauga, Ontario, operates in Pennsylvania, New Jersey, Maryland, Ohio, and California through TerrAscend Growth Corp., with retail operations in Canada and brands including The Apothecarium, Cookies, Kind Tree, Wana, and Valhalla. Its next observable step is a board decision on the ratio; any ratio it sets, and the effective date, will be publicly announced, and the authority it now holds expires on August 24, 2027.